Feeds
Pfizer Inc.'s $68 billion purchase of Wyeth will close Thursday after antitrust regulators in the U.S. and Canada cleared the deal, which will make Pfizer the world's largest drugmaker by revenue.
In the latest sign that Pfizer Inc.'s $68 billion purchase of Wyeth will go through, Wyeth's stock has been removed from two key investor indices.
The Food and Drug Administration will require two smoking-cessation drugs, Chantix and Zyban, to carry the agency's strongest safety warning over side effects including depression and suicidal thoughts.
Pfizer Inc.'s chief executive received a 2008 compensation package valued by The Associated Press at $14.79 million, up 17 percent from 2007, after a year when the drugmaker reorganized operations and set in motion a mega-acquistion.
Eager to dispel doubts about the difficulties of executing Pfizer Inc.'s $68 billion tie-up with Wyeth, Pfizer's CEO said it will be done more like microsurgery than just stitching two huge corporations together.
Investors worried about the recession have turned to a strategy of cherry-picking stocks — sending tech shares higher and industrials lower. The market's concerns Monday were focused on two fronts: the economic stimulus proposal now before the Senate, and a possible plan to give further aid to the nation's banks. Meanwhile, mostly negative economic data and news of more layoffs helped extend the gloomy mood that gave the market its worst January ever.
Drug giant Pfizer Inc.'s agreement to acquire rival Wyeth would give Wyeth directors a voice on Pfizer's board and includes hefty penalties aimed at preventing the deal from collapsing, according to a regulatory filing made Thursday.
The U.S. Patent & Trademark Office on Tuesday issued a notice allowing drugmaker Pfizer Inc. to correct a technical defect in one of the patents involving Pfizer's cholesterol medicine Lipitor, the world's top-selling drug.
Pfizer Inc.'s profit tripled in the third quarter, mainly because a huge charge depressed last year's results, despite flat sales. Its earnings narrowly beat Wall Street's earnings expectations.
Pfizer's stab at giving diabetics insulin without needles is getting more praise than prescriptions so far. Exubera, a powdered form inhaled through a special device, was introduced last year in a targeted launch to specialists, a debut analysts deemed disappointing. While doctors applaud Pfizer Inc.'s effort to find a new way to deliver insulin, some are concerned about the drug's long-term effects on the lungs, cost and insurance coverage.
Tons of Industry Released Drugs Taint US Water: AP ReportU.S. manufacturers, including major drugmakers, have legally released at least 271 million pounds of pharmaceuticals into waterways that often provide drinking water, contamination the federal government has consistently overlooked, according to an Associated Press investigation.
Drug Pitchmen: Actor, Doctor or Pfizer's OptionSurely the best message we can derive from the Dr. Robert Jarvik episode is that it may be time to rethink the advertising of prescription drugs
Pfizer to End Lipitor Campaign by JarvikThe ads featuring Dr. Robert Jarvik, a pioneer in artificial hearts, created false impressions, the company said.
Betting an Estate on Inhaled InsulinAlfred E. Mann is betting nearly $1 billion of his own money that he can succeed where Pfizer failed.
Drug Ads Raise Questions for Heart PioneerDr. Robert Jarvik's appearance in television ads for Lipitor has helped rekindle a smoldering debate.
Drug Approved. Is Disease Real? Doctors deny existence of FibromyalgiaThe first drug to treat fibromyalgia has been approved, but some dispute the very existence of the condition.
Drug Approved. Is Disease Real?The first drug to treat fibromyalgia has been approved, but some dispute the very existence of the condition.
F.D.A. Investigates Quit-Smoking DrugGovernment scientists are investigating whether a drug from Pfizer used to help smokers quit cigarettes also increases suicidal thoughts and violent behavior.
Maker of Lipitor Digs In to Fight Generic RivalMany patients on the cholesterol drug are switching to a cheaper alternative, but Pfizer is not letting its flagship product go down without a fight.
Pfizer's Birthplace, Soon Without PfizerThe drug giant will shut its plant on Flushing Avenue in Brooklyn, but still plans to help the neighborhood where the company began.
Log In | Register
